This last observation, together with the finding that aberrant recruitment and HDAC overexpression is associated with several pathological conditions including diabetes [137,138,139,140,141], suggests that targeted HDAC3 inhibition could be a potential strategic target to increase eNOS expression for the treatment of diabetes-associated vascular disease. The gene discussed is HDAC9; the disease is diabetes mellitus.